(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methanamine hydrochloride | 145733-69-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methanamine hydrochloride
• 英文别名: N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amine hydrochloride；[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methanamine;hydrochloride
• CAS: 145733-69-3
• 化学式: C₁₄H₁₃N₅*ClH
• 分子量: 287.752
• InChiKey: UIPBETMPKZPOAP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.41
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  80.5
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methanamine hydrochloride 、 2-丁基-3-氧杂-1-氮杂螺[4.4]壬-1-烯-4-酮 在 甲烷磺酸 作用下， 以 N-甲基吡咯烷酮 为溶剂， 160.0 ℃ 、20.0 kPa 条件下， 反应 2.5h， 以70.5%的产率得到厄贝沙坦
  参考文献：
  名称：

  Process for preparing an angiotensin II receptor antagonist

  摘要：

  制备厄贝沙坦的过程，用于制备其保护形式，或者其药用可接受的盐的过程，包括联苯胺衍生物和噁唑酮衍生物之间的反应。

  公开号：

  EP1749828A1
• 作为产物：
  描述：

  5-苯基四氮唑 、 4-溴苄胺盐酸盐 在 四(三苯基膦)钯 正己基锂 、 硼酸三甲酯 、 盐酸 、 sodium hydroxide 作用下， 以 乙二醇二甲醚 、 正己烷 为溶剂， 反应 3.0h， 生成 (2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methanamine hydrochloride
  参考文献：
  名称：

  Process for preparing an angiotensin II receptor antagonist

  摘要：

  制备厄贝沙坦的过程，用于制备其保护形式，或者其药用可接受的盐的过程，包括联苯胺衍生物和噁唑酮衍生物之间的反应。

  公开号：

  EP1749828A1

文献信息

• Pyrimidocycloalkanes as a II antagonists
  申请人：American Home Products Corporation

  公开号：US05234936A1

  公开（公告）日：1993-08-10

  There are disclosed compounds of the general formula I: ##STR1## wherein X is H, NR.sup.12 R.sup.13, OR.sup.14, CN, F, Cl, I, Br, perfluoroalkyl, alkyl, alkoxy, alkyl-OH, alkoxyalkyl, --(CH.sub.2).sub.n CO.sub.2 R.sup.14, --(CH.sub.2).sub.n CONR.sup.12 R.sup.13 ; Y is NR.sup.15, NR.sup.18 CR.sup.16 R.sup.17, CR.sup.16 R.sup.17 NR.sup.15 ; R.sup.1 is 5-tetrazolyl, CO.sub.2 R.sup.14, SO.sub.3 H, NHSO.sub.2 CH.sub.3, NHSO.sub.2 CF.sub.3 ; R.sup.2, R.sup.3 is H, alkyl, alkoxy, alkoxyalkyl, alkyl-OH perfluoroalkyl, aralkyl, CN, NO.sub.2, SO.sub.2 R.sup.19, --(CH.sub.2).sub.n CO.sub.2 R.sup.14, --(CH.sub.2).sub.n CONR.sup.12 R.sup.13, OR.sup.14, F, Cl, Br, I, NR.sup.12 R.sup.13 ; R.sup.4 -R.sup.11 is H, F, alkyl, alkoxy, alkoxyalkyl, --OCOR.sup.14, alkyl-OH, perfluoroalkyl, aralkyl, aryl, CN, NO.sub.2, SO.sub.2 R.sup.19, --(CH.sub.2).sub.n CO.sub.2 R.sup.14, --(CH.sub.2).sub.n CONR.sup.12 R.sup.13, OH, OR.sup.14, --NR.sup.12 R.sup.13, any two geminal groups can be O or CH.sub.2 ; R.sup.12, R.sup.13 is H, alkyl, aralkyl; R.sup.14 is H, alkyl, aralkyl, alkoxyalkyl; R.sup.15 is H, alkyl, --(CH.sub.2).sub.n CO.sub.2 R.sup.14, alkoxyalkyl, aralkyl, --(CH.sub.2).sub.n CONR.sup.12 R.sup.13, OR.sup.14, perfluoroalkyl, alkyl-OH, --COR.sup.14, --CONR.sup.12 R.sup.13 ; R.sup.16, R.sup.17 is H, alkyl, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, CN, NO.sub.2, SO.sub.2 R.sup.19, --(CH.sub.2).sub.n CO.sub.2 R.sup.14, --(CH.sub.2).sub.n CONR.sup.12 R.sup.13 ; R.sup.18 is H, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, OR.sup.14, --(CH.sub.2).sub.n CO.sub.2 R.sup.14, --(CH.sub.2).sub.n CONR.sup.12 R.sup.13, alkyl, --COR.sup.14, --CONR.sup.12 R.sup.13 ; R.sup.19 is alkyl, aralkyl; n is 0, 1, 2 or 3; m is 1-5; wherein alkyl is defined as 1-8 carbons, branched or straight chain; perfluoroalkyl is defined as 1-6 carbons; aralkyl is defined as 7-12 carbons or 7-12 carbons substituted with fluorine, bromine or chlorine; aryl is defined as 6-10 carbons or 6-10 carbons substituted with fluorine, bromine or chlorine and the pharmaceutically acceptable salts, solvates and hydrates thereof, which by virtue of their ability to antagonize angiotensin II are useful for the treatment of hypertension and congestive heart-failure. The compounds are also useful for reducing lipid levels in the blood plasma and are thus useful for treating hyperlipidemia and hypercholesterolemia. Also disclosed are processes for the production of said compounds and pharmaceutical compositions containing said compounds.

  公开了一般式I的化合物：其中X为H、NR.sup.12 R.sup.13、OR.sup.14、CN、F、Cl、I、Br、全氟烷基、烷基、烷氧基、烷基-OH、烷氧基烷基、--(CH.sub.2).sub.n CO.sub.2 R.sup.14、--(CH.sub.2).sub.n CONR.sup.12 R.sup.13；Y为NR.sup.15、NR.sup.18 CR.sup.16 R.sup.17、CR.sup.16 R.sup.17 NR.sup.15；R.sup.1为5-四唑基、CO.sub.2 R.sup.14、SO.sub.3 H、NHSO.sub.2 CH.sub.3、NHSO.sub.2 CF.sub.3；R.sup.2、R.sup.3为H、烷基、烷氧基、烷氧基烷基、烷基-OH全氟烷基、芳基烷基、CN、NO.sub.2、SO.sub.2 R.sup.19、--(CH.sub.2).sub.n CO.sub.2 R.sup.14、--(CH.sub.2).sub.n CONR.sup.12 R.sup.13、OR.sup.14、F、Cl、Br、I、NR.sup.12 R.sup.13；R.sup.4-R.sup.11为H、F、烷基、烷氧基、烷氧基烷基、--OCOR.sup.14、烷基-OH、全氟烷基、芳基烷基、芳基、CN、NO.sub.2、SO.sub.2 R.sup.19、--(CH.sub.2).sub.n CO.sub.2 R.sup.14、--(CH.sub.2).sub.n CONR.sup.12 R.sup.13、OH、OR.sup.14、--NR.sup.12 R.sup.13，任意两个相邻基团可以是O或CH.sub.2；R.sup.12、R.sup.13为H、烷基、芳基；R.sup.14为H、烷基、芳基、烷氧基烷基；R.sup.15为H、烷基、--(CH.sub.2).sub.n CO.sub.2 R.sup.14、烷氧基烷基、芳基烷基、--(CH.sub.2).sub.n CONR.sup.12 R.sup.13、OR.sup.14、全氟烷基、烷基-OH、--COR.sup.14、--CONR.sup.12 R.sup.13；R.sup.16、R.sup.17为H、烷基、烷氧基烷基、烷基-OH、全氟烷基、芳基烷基、CN、NO.sub.2、SO.sub.2 R.sup.19、--(CH.sub.2).sub.n CO.sub.2 R.sup.14、--(CH.sub.2).sub.n CONR.sup.12 R.sup.13；R.sup.18为H、烷氧基烷基、烷基-OH、全氟烷基、芳基烷基、OR.sup.14、--(CH.sub.2).sub.n CO.sub.2 R.sup.14、--(CH.sub.2).sub.n CONR.sup.12 R.sup.13、烷基、--COR.sup.14、--CONR.sup.12 R.sup.13；R.sup.19为烷基、芳基；n为0、1、2或3；m为1-5；其中烷基定义为1-8碳原子、支链或直链；全氟烷基定义为1-6碳原子；芳基烷基定义为7-12碳原子或7-12碳原子取代氟、溴或氯；芳基定义为6-10碳原子或6-10碳原子取代氟、溴或氯，以及其药学上可接受的盐、溶剂化合物和水合物，由于其对抗肾素II的能力，可用于治疗高血压和充血性心力衰竭。这些化合物还可用于降低血浆中的脂质水平，因此可用于治疗高脂血症和高胆固醇血症。还公开了生产该化合物的方法和含有该化合物的药物组合物。
• Process for Preparing an Angiotensin II Receptor Antagonist
  申请人：Bessa Belmunt Jordi

  公开号：US20080281097A1

  公开（公告）日：2008-11-13

  Process for preparing angiotensin II receptor antagonists, in particular irbesartan, protected forms for the preparation thereof, or a pharmaceutically acceptable salt thereof, that comprises the reaction between a biphenylamino derivative and an oxazolone derivative. New intermediates are useful for the preparation of angiotensin II receptor antagonists.

  制备血管紧张素II受体拮抗剂（特别是厄贝沙坦）的过程，其保护形式的制备，或其药学上可接受的盐，包括联苯胺衍生物和噁唑烷衍生物之间的反应。新的中间体对于制备血管紧张素II受体拮抗剂是有用的。
• Substituted quinazolines as angiotensin II antagonists
  申请人：American Home Products Corporation

  公开号：US05187168A1

  公开（公告）日：1993-02-16

  There are disclosed compounds of the general formula I: ##STR1## wherein A is --CR.sup.7 .dbd.CR.sup.8 --; Z is --CR.sup.7 .dbd.CR.sup.8 --; X is H, NR .sup.9 R.sup.10, OR.sup.11, CN, F, Cl, I, Br, perfluoroalkyl, alkyl,alkoxy, alkyl-OH, alkoxyalkyl, --(CH.sub.2).sub.n CO.sub.2 R.sup.11,--(CH.sub.2).sub.n CONR.sup.9 R.sup.10 ; Y is NR.sup.13,NR.sup.13 CR.sup.12 R.sup.14, CR.sup.12 R.sup.14 NR.sup.13 ; R.sup.1 is 5-tetrazolyl, CO.sub.2 R.sup.11,SO.sub.3 H, NHSO.sub.2 CH.sub.3, NHSO.sub.2 CF.sub.3 ; R.sup.2,R.sup.3,R.sup.4,R.sup.7 R.sup.8 is H, alkyl, alkoxy, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, CN, NO.sub.2, SO.sub.2 R.sup.13, --(CH.sub.2).sub.n CO.sub.2 R.sup.11,--(CH.sub.2).sub.n CONR.sup.9 R.sup.10, OR.sup.11,F,Cl,Br,I,NR.sup.9 R.sup.10 ; R.sup.5 is alkyl, alkoxy, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, H, --CN, NO.sub.2, SO.sub.2 R.sup.13,--(CH.sub.2).sub.n CO.sub.2 R.sup.11, --(CH.sub.2).sub.n CONR.sup.9 R.sup.10, --OH,OR.sup.11,F,Cl,Br,I,NR.sup.9 R.sup.10 ; R.sup.9,R.sup.10 is H, alkyl, alkoxyalkyl,alkyl-OH, perfluoroalkyl, aralkyl; R.sup.11 is H, alkyl, aralkyl, alkoxyalkyl; R.sup.12,R.sup.14 is H, alkyl, alkoxy, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, CN, NO.sub.2, SO.sub.2 R.sup.13, --(CH.sub.2).sub.n CO.sub.2 R.sup.11, --(CH.sub.2).sub.n CONR.sup.9 R.sup.10 ; R.sup.13 is H, OR.sup.11, alkyl, perfluoroalkyl, aralkyl, --(CH.sub.2).sub.n CO.sub.2 R.sup.11,--(CH.sub.2).sub.n CONR.sup.9 R.sup.10 ; wherein alkyl is defined as 1-8 carbons, branched or straight chain; perfluoroalkyl is defined as 1-6 carbons; aralkyl is defined as 7-12 carbons or 7-12 carbons substituted with fluorine, bromine or chlorine and the phamaceutically acceptable salts, solvates and hydrates thereof, which by virtue of their ability to antagonize angiotensin II are useful for the treatment of hypertension and congestive heart-failure. The compounds are also useful for reducing lipid levels in the blood plasma and are thus useful for treating hyperlipidemia and hypercholesterolemia. Also disclosed are processes for the production of said compounds and pharmaceutical compositions containing said compounds.

  公开了一般式I的化合物：##STR1## 其中A为--CR.sup.7 .dbd.CR.sup.8 --; Z为--CR.sup.7 .dbd.CR.sup.8 --; X为H、NR .sup.9 R.sup.10、OR.sup.11、CN、F、Cl、I、Br、全氟烷基、烷基、烷氧基、烷基-OH、烷氧基烷基、--(CH.sub.2).sub.n CO.sub.2 R.sup.11、--(CH.sub.2).sub.n CONR.sup.9 R.sup.10；Y为NR.sup.13、NR.sup.13 CR.sup.12 R.sup.14、CR.sup.12 R.sup.14 NR.sup.13；R.sup.1为5-四唑基、CO.sub.2 R.sup.11、SO.sub.3 H、NHSO.sub.2 CH.sub.3、NHSO.sub.2 CF.sub.3；R.sup.2、R.sup.3、R.sup.4、R.sup.7 R.sup.8为H、烷基、烷氧基、烷氧基烷基、烷基-OH、全氟烷基、芳基烷基、CN、NO.sub.2、SO.sub.2 R.sup.13、--(CH.sub.2).sub.n CO.sub.2 R.sup.11、--(CH.sub.2).sub.n CONR.sup.9 R.sup.10、OR.sup.11、F、Cl、Br、I、NR.sup.9 R.sup.10；R.sup.5为烷基、烷氧基、烷氧基烷基、烷基-OH、全氟烷基、芳基烷基、H、--CN、NO.sub.2、SO.sub.2 R.sup.13、--(CH.sub.2).sub.n CO.sub.2 R.sup.11、--(CH.sub.2).sub.n CONR.sup.9 R.sup.10、--OH、OR.sup.11、F、Cl、Br、I、NR.sup.9 R.sup.10；R.sup.9、R.sup.10为H、烷基、烷氧基烷基、烷基-OH、全氟烷基、芳基烷基；R.sup.11为H、烷基、芳基烷基、烷氧基烷基；R.sup.12、R.sup.14为H、烷基、烷氧基、烷氧基烷基、烷基-OH、全氟烷基、芳基烷基、CN、NO.sub.2、SO.sub.2 R.sup.13、--(CH.sub.2).sub.n CO.sub.2 R.sup.11、--(CH.sub.2).sub.n CONR.sup.9 R.sup.10；R.sup.13为H、OR.sup.11、烷基、全氟烷基、芳基烷基、--(CH.sub.2).sub.n CO.sub.2 R.sup.11、--(CH.sub.2).sub.n CONR.sup.9 R.sup.10；其中烷基定义为1-8个碳原子，支链或直链；全氟烷基定义为1-6个碳原子；芳基烷基定义为7-12个碳原子或7-12个碳原子被氟、溴或氯取代；以及其药学上可接受的盐、溶剂和水合物。由于其拮抗血管紧张素II的能力，这些化合物对治疗高血压和充血性心力衰竭有用。这些化合物也对降低血浆中的脂质水平有用，因此对治疗高脂血症和高胆固醇血症有用。还公开了生产所述化合物的方法和含有所述化合物的药物组合物。
• Fused pyrimidines as angiotensin II antagonists
  申请人：American Home Products Corporation

  公开号：US05236925A1

  公开（公告）日：1993-08-17

  There are disclosed compounds of the general formula I: ##STR1## wherein A is O, S, NR.sup.6 ; Z is O, S, NR.sup.6 ; X is H, NR.sup.9 R.sup.10, OR.sup.11, CN, F, Cl, I, Br, perfluoroalkyl, alkyl, alkyl-OH, alkoxyalkyl, --(CH.sub.2).sub.n CO.sub.2 R.sup.11, --(CH.sub.2).sub.n CONR.sup.9 R.sup.10 ; Y is NR.sup.13 CR.sup.12 R.sup.14 ; R.sup.1 is 5-tetrazolyl, CO.sub.2 R.sup.11, SO.sub.3 H, NHSO.sub.2 CH.sub.3, NHSO.sub.2 CF.sub.3 ; R.sup.2, R.sup.3, R.sup.4, R.sup.7, R.sup.8 is H, alkyl, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, CN, NO.sub.2, SO.sub.2 R.sup.13, --(CH.sub.2).sub.n CO.sub.2 R.sup.11, --(CH.sub.2).sub.n CONR.sup.9 R.sup.10, OR.sup.11, F, Cl, Br, I, NR.sup.9 R.sup.10 ; R.sup.5 is alkyl, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, H, --CN, NO.sub.2, SO.sub.2 R.sup.13, --(CH.sub.2).sub.n CO.sub.2 R.sup.11, --(CH.sub.2).sub.n CONR.sup.9 R.sup.10 ; R.sup.6 is H, alkyl, aralkyl; R.sup.9, R.sup.10 is H, alkyl, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl; R.sup.11 is H, alkyl, aralkyl, alkoxyalkyl; R.sup.12, R.sup.14 is H, alkyl, alkoxyalkyl, alkyl-OH, perfluoroalkyl, aralkyl, CN, NO.sub.2, SO.sub.2 R.sup.13, --(CH.sub.2).sub.n CO.sub.2 R.sup.11, --(CH.sub.2).sub.n CONR.sup.9 R.sup.10 ; R.sup.13 is H, OR.sup.11, alkyl, perfluoroalkyl, aralkyl, --(CH.sub.2).sub.n CO.sub.2 R.sup.11, --(CH.sub.2).sub.n CONR.sup.9 R.sup.10 ; wherein alkyl is defined as 1-8 carbons, branched or straight chain; perfluoroalkyl is defined as 1-6 carbons; aralkyl is defined as 7-12 carbons or 7-12 carbons substituted with fluorine, bromine or chlorine and the pharmaceutically acceptable salts, solvates and hydrates thereof, which by virtue of their ability to antagonize angiotensin II are useful for the treatment of hypertension and congestive heart-failure. The compounds are also useful for reducing lipid levels in the blood plasma and are thus useful for treating hyperlipidemia and hypercholesterolemia. Also disclosed are processes for the production of said compounds and pharmaceutical compositions containing said compounds.

  公式I的化合物被揭示，其中A是O、S、NR.sup.6；Z是O、S、NR.sup.6；X是H、NR.sup.9R.sup.10、OR.sup.11、CN、F、Cl、I、Br、全氟烷基、烷基、烷基-OH、烷氧基烷基、--(CH.sub.2).sub.nCO.sub.2R.sup.11、--(CH.sub.2).sub.nCONR.sup.9R.sup.10；Y是NR.sup.13CR.sup.12R.sup.14；R.sup.1是5-四唑基、CO.sub.2R.sup.11、SO.sub.3H、NHSO.sub.2CH.sub.3、NHSO.sub.2CF.sub.3；R.sup.2、R.sup.3、R.sup.4、R.sup.7、R.sup.8是H、烷基、烷氧基烷基、烷基-OH、全氟烷基、芳基烷基、CN、NO.sub.2、SO.sub.2R.sup.13、--(CH.sub.2).sub.nCO.sub.2R.sup.11、--(CH.sub.2).sub.nCONR.sup.9R.sup.10、OR.sup.11、F、Cl、Br、I、NR.sup.9R.sup.10；R.sup.5是烷基、烷氧基烷基、烷基-OH、全氟烷基、芳基烷基、H、--CN、NO.sub.2、SO.sub.2R.sup.13、--(CH.sub.2).sub.nCO.sub.2R.sup.11、--(CH.sub.2).sub.nCONR.sup.9R.sup.10；R.sup.6是H、烷基、芳基烷基；R.sup.9、R.sup.10是H、烷基、烷氧基烷基、烷基-OH、全氟烷基、芳基烷基；R.sup.11是H、烷基、芳基烷基、烷氧基烷基；R.sup.12、R.sup.14是H、烷基、烷氧基烷基、烷基-OH、全氟烷基、芳基烷基、CN、NO.sub.2、SO.sub.2R.sup.13、--(CH.sub.2).sub.nCO.sub.2R.sup.11、--(CH.sub.2).sub.nCONR.sup.9R.sup.10；R.sup.13是H、OR.sup.11、烷基、全氟烷基、芳基烷基、--(CH.sub.2).sub.nCO.sub.2R.sup.11、--(CH.sub.2).sub.nCONR.sup.9R.sup.10；其中烷基定义为1-8个碳，分支或直链；全氟烷基定义为1-6个碳；芳基烷基定义为7-12个碳或7-12个碳被氟、溴或氯取代；以及其药学上可接受的盐、溶剂和水合物。这些化合物因其拮抗血管紧张素II的能力而用于治疗高血压和充血性心力衰竭。该化合物也用于降低血浆中的脂质水平，因此可用于治疗高脂血症和高胆固醇血症。此外，还揭示了制备该化合物的过程和含有该化合物的药物组合物。
• PROCESS FOR PREPARING AN ANGIOTENSIN II RECEPTOR ANTAGONIST
  申请人：Farmaprojects, S.A.

  公开号：EP1919469B1

  公开（公告）日：2011-02-16